Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential - GBI Research Reports

Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential

Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential - GBI Research Reports
Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential
Published Dec 22, 2010
126 pages — Published Dec 22, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, 'Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential', which provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin's Lymphoma (NHL).

Scope

The report covers:
- Data and analysis on the oncology market in India.
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the oncology market includes both Indian players and foreign players.
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Indian oncology market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
- Build effective strategies to launch their pipeline products by identifying potential of the market.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying each indication's growth rate.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

  
Source:
Document ID
GBIHC058MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
List of Tables62
List of Figures82
Oncology Market in India: Introduction102
GBI Research Report Guidance111
Oncology Market in India: Market Characterization1213
Market Size121
Annual Cost of Treatment131
Treatment Usage Pattern141
Diseased Population151
Treated Population161
Drivers171
High Spending By Big Pharmaceutical Companies for Drug Trials171
Larger Population Base171
High Government Support and Initiatives181
Barriers191
Counterfeit Medical Products191
Unfavorable Patent Law for Bigger Companies191
Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Cancer Market Growth191
Poor Infrastructure and Insufficient Trained Manpower201
More than 80 Molecules to be launched Over the Next Seven Years, Leading to More Competition201
Case Studies211
Unfavorable Patent Law for Bigger Foreign Companies, Roche versus Cipla212
Unfavorable Patent Law for Bigger Foreign Companies, Novartis Glivec232
Oncology Market in India: Therapeutic Landscape2529
Introduction251
Breast Cancer251
Market Size251
Average Annual Cost of Treatment261
Treatment Usage Pattern271
Diseased Population281
Treated Population291
Drivers291
Increasing Per Capita Income291
Late Age at First Childbirth291
Fewer Children and Shorter Duration of Breast-Feeding301
Restraints301
Unawareness about Mammography301
Unavailability of Experienced Medical Specialists301
Colorectal Cancer311
Market Size311
Annual Cost of Treatment321
Treatment Usage Pattern331
Disease Population341
Treated Population351
Drivers351
Migration from Rural to Urban Areas, Adoption of Western Nutritional Food Habits and Urbanization351
Ageing Population351
Restraints361
Affordability361
Tough Competition from Local Companies and Huge Generic Market361
Complex Government Regulation and Limited-to-No Reimbursement of Expensive Patented Oncology Drugs361
Prostate Cancer371
Market Size371
Annual Cost of Treatment381
Drivers391
Advancement of Innovative Targeted and Combination Therapies391
Dietary Fats and Fiber391
Restraints391
Huge Generic Market391
Treatment Usage Pattern391
Disease Population401
Treated Population411
Lung Cancer421
Market Size421
Annual Cost of Treatment431
Drivers441
Increased Smoking Prevalence441
Increasing Middle Class Population with Growing Economic Clout441
Increasing Air Pollution441
Restraints441
Low Treatment Rate441
Generic Dominated Market441
Treatment Usage Pattern451
Diseased Population461
Treated Population471
Non-Hodgkin s Lymphoma481
Market Size481
Annual Cost of Treatment491
Drivers501
Increasing HIV Population in India501
Higher Diagnosis Rate501
Increasing Incidence Population501
Restraints501
Less Affordability501
Huge Generic Market501
Treatment Usage Pattern511
Diseased Population521
Treated Population531
Oncology in India: Regulatory Landscape5413
Major Regulatory Bodies in India541
The Central Drugs Standard Control Organization (CDSCO)541
State Drug Regulatory Authority (SDRA)551
IPR Protection in India562
Effect of Patent Laws on Pharmaceutical Production in India581
Key Impact of Newer Patent Laws on India581
Key Regulations for Conducting Oncology Research in India591
Government Initiatives to Support Oncology Research in India601
Focus Areas611
Oncology in India: Pricing and Reimbursements621
Pricing of Oncology Drugs in India623
Reimbursement of Oncology Drugs in India651
Cancer Health Insurance Policies651
Insurance Policy for Cancer Treatment in India661
Oncology in India: Pipeline Analysis6721
Key Area Focus for R&D in India671
Pipeline Segmentation by Clinical Phase of Development671
Pipeline Segmentation by Indication681
Lung Cancer691
Breast Cancer701
Colorectal Cancer711
Non-Hodgkin s Lymphoma721
Prostate Cancer731
Key Late Stage Pipeline Drugs741
Lung Cancer741
Stimuvax741
AMG 706 (motesanib)741
Vargatef (BIBF 1120)751
Breast Cancer751
Afinitor (everolimus)751
BSI-201761
NeuVax761
Colorectal Cancer771
Aflibercept771
Brivanib781
OncoVAX791
TroVAX801
KRX-0401 (perifosine)801
Non-Hodgkin s Lymphoma811
BiovaxID811
Afinitor (everolimus)821
Reviroc831
LY317615 (enzastaurin)831
Prostate Cancer841
Provenge (sipuleucel-T)841
Denosumab851
Aflibercept (VEGF Trap)861
Ipilimumab861
CB7630 (abiraterone acetate)871
Oncology in India: Competitive Landscape8824
Key Indian Players in the Indian Oncology Market881
Dr. Reddy s Lab881
Company Overview881
SWOT Analysis891
Marketed Products and Product Pipeline901
Merger, Acquisition and Partnership Deals911
Piramal Healthcare911
Company Overview911
SWOT Analysis921
Marketed Products and Product Pipeline931
Merger, Acquisition and Partnership Deals941
Biocon Limited951
Company Overview951
SWOT Analysis951
Marketed Products and Product Pipeline961
Cipla Ltd.971
Company Overview971
SWOT Analysis982
Key Foreign Players in the Indian Oncology Market1001
Sanofi-Aventis1001
Company Overview1001
SWOT Analysis1002
Major Marketed Products and Pipeline Products1022
F. Hoffmann-La Roche Ltd/Genentech, Inc.1041
Company Overview1041
SWOT Analysis1051
Major Marketed Products and Pipeline Products1061
AstraZeneca1071
Overview1071
SWOT Analysis1071
Major Marketed Products and Pipeline Products1081
GlaxoSmithKline1091
Overview1091
SWOT Analysis1092
Major Marketed Products and Pipeline Products1111
Deals Landscape11211
Mergers and Acquisitions1121
Deals by Year1121
Deals by Type1131
Deal by Value1141
Top 10 M&A Deals1151
Strides to Acquire 50% Stake in Onco Therapies and Onco Laboratories from Aspen1161
Mitsui to Acquire 5% Stake in Arch Pharmalabs1161
Biocon to Acquire Minority Stake in Biocon Biopharmaceuticals1161
UB Group Sells 10.27% Stake in Aventis Pharma to Hoechst1161
Sanofi-Aventis Acquires Majority Stake in Shantha Biotechnics1161
Daiichi Sankyo Acquires Majority Stake in Ranbaxy Laboratories1171
Arch Pharmalabs Acquires 70% Stake in Benzochem Lifesciences1171
Fresenius Kabi Acquires 90.9% Stake in Dabur Pharma1171
Ranbaxy Laboratories Acquires 25.15% Stake in Zenotech Laboratories1171
Aspen Pharmacare Acquires Stake in Onco Therapies from Strides Arcolab1181
Licensing Agreements1181
Deals by Year1181
Deals by Value1191
Key Takeaway1201
Top 10 Licensing Deals1201
Takeda Pharmaceutical Enters into Collaboration Agreement with Alnylam Pharmaceuticals1201
Algeta Signs Licensing Agreement with Bayer1201
BioInvent and ThromboGenics Enter into an Agreement with Roche1201
Sanofi-Aventis Enters into a Licensing Agreement with Merrimack Pharmaceuticals1211
Genentech Enters into Licensing Agreement with CGI Pharmaceuticals1211
Pfizer Enters into Licensing Agreement with Coley Pharmaceutical1211
Novacea Enters into Licensing Agreement with Schering-Plough for Asentar1211
Merck Enters into Licensing Agreement with Lpath1221
Merck Signs an Agreement with Idera Pharmaceuticals1221
Taiho Pharmaceutical Signs Licensing Agreement with Sanofi-Aventis1221
Appendix1234
Market Definitions1231
Abbreviations1231
Research Methodology1242
Coverage1241
Secondary Research1241
Primary Research1251
Expert Panel Validation1251
Contact Us1251
Disclaimer1251
Sources1261

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential" Dec 22, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Oncology-Market-in-India-to-2017-Limited-Patient-Affordability-for-High-Priced-Biologics-Lowers-Market-Potential-2115-125>
  
APA:
GBI Research Reports. (2010). Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential Dec 22, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Oncology-Market-in-India-to-2017-Limited-Patient-Affordability-for-High-Priced-Biologics-Lowers-Market-Potential-2115-125>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.